Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

CLASS ACTION UPDATE for BMRN, AMRN and Z: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / November 19, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BMRN Shareholders Click Here: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21406&wire=1
AMRN Shareholders Click Here: https://www.zlk.com/pslra-1/amarin-corporation-plc-loss-submission-form?prid=21406&wire=1
Z Shareholders Click Here: https://www.zlk.com/pslra-1/zillow-group-inc-information-request-form?prid=21406&wire=1

* ADDITIONAL INFORMATION BELOW *

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BMRN Lawsuit on behalf of: investors who purchased January 13, 2020 - September 3, 2021
Lead Plaintiff Deadline : December 22, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21406&wire=1

According to the filed complaint, during the class period, BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Amarin Corporation Plc (NASDAQ:AMRN)

AMRN Lawsuit on behalf of: investors who purchased December 5, 2018 - June 21, 2021
Lead Plaintiff Deadline : December 23, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/amarin-corporation-plc-loss-submission-form?prid=21406&wire=1

According to the filed complaint, during the class period, Amarin Corporation Plc made materially false and/or misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company's business and future prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Zillow Group, Inc. (NASDAQ:Z)

Z Lawsuit on behalf of: investors who purchased February 10, 2021 - November 2, 2021
Lead Plaintiff Deadline : January 18, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/zillow-group-inc-information-request-form?prid=21406&wire=1

According to the filed complaint, during the class period, Zillow Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) despite operational improvements, the Company experienced significant unpredictability in forecasting home prices for its Zillow Offers business; (2) such unpredictability, as well as labor and supply shortages, led to a backlog of inventory; (3) as a result of the foregoing, the Company was reasonably likely to wind-down its Zillow Offers business, which would have a material adverse impact on its financial results; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/673822/CLASS-ACTION-UPDATE-for-BMRN-AMRN-and-Z-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.